News | Focused Ultrasound Therapy | April 12, 2017

Theraclion Reports Positive Long-Term Echopulse Results in Breast Fibroadenoma

Study results reveal mean volume reduction at 24 months; treatment is safe and well-tolerated by patients

April 12, 2017 — Theraclion announced results of a study evaluating the long-term assessment of breast fibroadenoma (benign tumor) volume reduction following treatment with the company’s Echopulse, a non-invasive treatment employing ultrasound-guided high-intensity focused ultrasound. The study, entitled “Long-term efficacy of ultrasound-guided high-intensity focused ultrasound (US-guided HIFU) treatment of breast fibroadenoma,” was published online in the March 2017 issue of the Journal of Therapeutic Ultrasound and is available online.

The study assessed a total of 20 female patients with 26 breast fibroadenomas (BFAs) before and for up to 24 months following echotherapy treatment with Echopulse. Nineteen BFAs received a single treatment and seven BFAs a second treatment six to nine months after the initial session. BFA volume was measured by ultrasound. Patient satisfaction on cosmetic results and symptom relief were surveyed and safety and tolerability was recorded. The study demonstrated consistent echotherapy results confirmed at 24 months:

  • Mean BFA volume was significantly reduced by 77.32 percent after a single procedure and by 90.47 percent after two procedures at 24 months follow up;
  • No cases of re-growth of treated lesions were observed during the 24 months follow-up;
  • Treatment was very well-tolerated regardless of whether one or two echotherapy sessions were performed. Side effects were mild and transient and resolved completely; no serious side effects were observed;
  • Of the 20 patients who completed a satisfaction survey, all 20 (100 percent) were completely or highly satisfied with the cosmetic results and 19 of 20 (95 percent) were completely or highly satisfied concerning symptom disappearance; and
  • Authors concluded that “US-guided HIFU represents a promising non-invasive method with sustainable FA volume reduction and patient’s tolerability. Although one treatment is highly efficient, the volume reduction can be increased with second treatment.”

Roussanka Kovatcheva, M.D., professor of endocrinology at the University Hospital of Endocrinology of Sofia, Bulgaria, and Principal Investigator said, “Our results show the long-term efficacy and safety of US-guided HIFU generated by Theraclion’s Echopulse in patients with breast fibroadenomas. US-guided HIFU is definitely an effective non-invasive alternative to surgery enabling more than 90 percent volume reduction without re-growth or serious adverse events.”

For more information: www.jtultrasound.biomedcentral.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
California Women In Favor of Extending State's Breast Density Inform Law
News | Breast Density | June 15, 2018
A recent survey of California women found that 95 percent of respondents want the state’s breast density inform law to...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Overlay Init